top of page
Search

HOW DO WE SCALE WOMENS HEALTH?

Writer: Sten André Rigedahl
Sten André Rigedahl
Sep 18
4 min read

Updated: 1 hour ago



Yesterday I attended a fascinating discussion at Venture Café London on a question that deserves far more attention:


How do we actually scale women’s health?

The panel was hosted by the Nexus Women’s Health Tech Collective, a Barclays-backed accelerator supporting around 40 founders, with Shamik Parekh, Vandana Subramanian and Dr. Chrysi Sergaki sharing perspectives from investment, entrepreneurship, healthcare and regulation.


I spend a lot of my time around capital, technology and businesses trying to solve meaningful problems, and one thing from the discussion really stayed with me:

We do not have a shortage of innovation in women’s health. We have a problem getting the right capital, regulation and commercial structures around that innovation.


The “wellness trap”

One of the most interesting discussions was around why so many women’s health businesses end up positioning themselves as wellness companies.


The answer is often very simple:


That is where the money is easier to access

Wellness can be launched faster. It has fewer regulatory hurdles. It can be sold directly to consumers. Revenue can arrive sooner.


That fits the traditional venture capital model.

Clinical innovation does not always work like that.

A medical device, diagnostic or therapeutic solution may need years of research, trials, validation and regulatory approvals before meaningful revenues appear.


Yet founders are still asked:

“When will you generate revenue?”

Sometimes we are trying to force healthcare innovation into a financing model that was never designed for healthcare.

And once a genuinely clinical solution has been pushed into the wellness category, it can be extremely difficult to move it back.


For me, that raises a bigger question:

Is women’s health underfunded, or do we simply not have enough of the right investors in the room?

Investors who understand that transformational healthcare may require a 10-year horizon rather than a three-year exit.


Build for Patients, Not Investors

Another point I strongly agreed with was made by Vandana:

Build for the patient and the healthcare system — not for the investor.


Capital should enable the mission. It should not define the mission.

At the same time, founders need to understand that brilliant science on its own is not enough.


You need to know:

  • How will the product be regulated?

  • Who will pay for it?

  • Who will distribute it?

  • How does it enter hospitals?

  • What clinical evidence is required?

  • What is the reimbursement pathway?

  • How is the IP protected?

  • And what does commercialisation actually look like?

Increasingly, this preparation is not something investors want to see later. It is the ticket through the door.



Regulation Should Start on Day One

One of the strongest practical messages from the evening was that founders need to think about regulation from the very beginning.

Every study.

Every trial.

Every piece of data.

Ideally, each one should be moving the company closer towards clinical validation and regulatory approval.


Otherwise, founders can spend years and significant amounts of capital generating evidence that cannot actually be used later.

The UK already has support mechanisms through the MHRA, together with accelerated pathways such as ILAP and IDAP for innovative products addressing unmet medical needs.


Yet many founders simply do not know these pathways exist.

That is an ecosystem problem we can fix.



Think Globally from the Start

I also liked the discussion around international market strategy.

The biggest market is not necessarily the best market to enter first.

Sometimes a smaller country or a different regulatory jurisdiction can provide a faster clinical or regulatory proof point.


That validation can then dramatically strengthen the company when approaching investors, hospitals and larger markets.

This is something I see repeatedly across industries.


The smartest route is not always the most obvious route.





NHS, Insurers and the Commercial Reality


The NHS naturally came up.

Founders can spend years working on grants and pilots without ever developing a truly scalable commercial model.


But the US ie. is not automatically easier.

Instead of one healthcare system, founders may face multiple insurers, multiple reimbursement structures and multiple decision-makers.

There is no perfect market. There are simply different battles.
The key is understanding which battle your company is equipped to fight.

An interesting point from the audience was also the gap in UK private insurance around menopause and chronic women's health conditions.

Again, the answer comes back to evidence.

Healthcare systems rarely change overnight.

But evidence accumulates.

And eventually, compelling clinical data becomes very difficult to ignore.



Are we investing in what is easy or in what matters?

Perhaps the most important question of the evening was around where investment capital is actually going.


A lot of money has gone into the delivery layer:

  • Apps.

  • Platforms.

  • Wellness services.

  • Consumer solutions.


They are easier to build and easier to launch.


But many struggle once the first pool of paying customers has been exhausted.

Meanwhile, potentially transformative clinical technologies may struggle to raise the relatively small amounts of early capital needed to validate the science.

That creates a question that goes far beyond women’s health:

Are we investing in what is easiest to commercialise — or in what has the potential to create the greatest impact?

For me, this is where capital and purpose have to meet.

Women’s health represents an enormous economic opportunity.

But much more importantly, it represents an opportunity to improve the quality of life of hundreds of millions of women around the world

The founders are there.

The science is increasingly there.

The technology is there.


Now we need the capital, healthcare systems and regulatory frameworks to catch up.

And perhaps we also need a slightly different definition of return.

Not simply:

How quickly can we exit?

But:

How much human value can we create, and how do we build an investable model around it?

That is a conversation I would very much like to continue.


Reach out if you want to discuss grant funding, equity and debt finance and more.

Sten André Rigedahl




 
 
 

Comments


  • LinkedIn
  • YouTube
  • Instagram
  • Facebook
  • X
  • Medium

©2021-  Sten André Rigedahl

bottom of page